[183 Pages Report] The global tumor ablation market is estimated to grow at a CAGR of 12.5% to reach USD 580.1 Million by 2021. Technological advancements in the field of tumor ablation coupled with increased procedural safety profile, rising market demand of minimal invasive tumor ablation techniques, increasing prevalence of cancer across the globe, as well as growing number of public-private initiatives & funding to support ongoing research activities related to tumor ablation are propelling the growth of the market. However, factors such as unfavorable regulatory policies and cost containment measures adopted by various governments are restraining the optimal market growth.

This market has evolved significantly in the last two decades. This can primarily be attributed to the emergence of various technologically advanced devices, such as multi-polar and bipolar electrodes, temperature-controlled and fluid-cooled ablation catheters, and imaging and contact force measuring sensors. Most of the leading manufacturers and new market entrants are investing heavily in R&D activities to develop novel tumor ablation products and to expand the clinical application profile of their existing tumor ablation products. In line with this strategy, from 2013 to 2016, the global market witnessed several initiatives by key players (Covidien, Plc, Medtronic, Inc., NeuWave Medical, Inc., and SonaCare Medical, LLC, among others) to strengthen their R&D capabilities.

In the published report, the global tumor ablation market is segmented on the basis of technology, mode of treatment, applications, and regions. On the basis of technology, the radiofrequency ablation accounted for the largest share in the global market, in 2016, which can primarily be attributed to its ease of treatment (as compared to open surgical procedure), its proven clinical efficacy and safety profile, and ongoing developments & commercialization of technologically advanced radiofrequency tumor ablation systems.

Geographically, the global market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World. In 2016, Geographically, North America is estimated to command the largest share of the global market in 2016, followed by Europe. The large market share of the North American region can be attributed to high prevalence and incidence of major types of cancer (such as liver, lung, kidney, and bone metastasis) in the region, rising inclination of patients towards minimally invasive procedures for cancer treatment, and increasing government funding for cancer research. However, unfavorable regulatory scenario and cost containment measures adopted by government are negatively affecting the growth of the market in this region.

As of 2016, Medtronic plc (Ireland) held the leadership position in the global tumor ablation market. Over the past three years, the company has adopted new product launches, product enhancements, and geographic expansion as its key business strategies to ensure its dominance in this market. Angiodynamics, Inc. (U.S.), Boston Scientific Corporation (U.S.), Galil Medical, Inc. (U.S.), EDAP TMS S.A. (France), Healthtronics, Inc. (U.S.), Medtronic, Plc (U.S.), Mermaid Medical, Inc. (Denmark), Mesonix, Inc. (U.S.), Neuwave Medical, Inc. (U.S.) and Sonacare Medical, LLC (U.S.) are some of the other key players operating in the market.

To know about the assumptions considered for the study, download the pdf brochure

Scope of the Report

This research report categorizes the tumor ablation market into the following segments:

Global Market, by Technology

Radiofrequency (RF) Ablation

Microwave Ablation

Cryoablation

Other Technologies

Global Market, by Mode of Treatment

Percutaneous Ablation

Laparoscopic Ablation

Surgical Ablation

Global Market, by Mode of Treatment

Liver Cancer

Lung Cancer

Kidney Cancer

Bone Metastasis

Others

Global Market, by Region

North America U.S. Canada

Europe Italy Germany France U.K. Spain Rest of Europe

Asia-Pacific Japan China India Rest of Asia-Pacific

Rest of the World (RoW)

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company�s specific needs. The following customization options are available for tumor ablation market report:

Product Analysis

Product Matrix which gives a detailed comparison of the product portfolios of each company

Geographical Analysis

Further breakdown of the RoAPAC market into the Australia, Rest of Pacific, and Rest of Asia

Further breakdown of the RoW market into the Middle East, Latin America, and Africa

Company Information

Detailed analysis and profiling of additional market players (Up to 5)

The tumor ablation market is projected to grow from an estimated USD 321.9 Million in 2016 to USD 580.1 million by 2021 at a CAGR of 12.5%.

Growth in the tumor ablation market is mainly driven by the significant geriatric population and rising cancer patient population across the globe, and ongoing technological advancements in the field of tumor ablation products.

By technology, the microwave ablation segment is expected to grow at the highest rate during the forecast period in the tumor ablation market

The microwave tumor ablation technology is the fastest-growing ablation technology segment that is currently being used to treat various cancers (such as liver, lung, and kidney).

Growth in the in microwave ablation segment is attributed to increasing private funding for novel product development of microwave ablation, its significant efficiency over other ablation technologies, and growing adoption of the microwave tumor ablation procedure among healthcare professionals to treat various cancers.

By mode of treatment, surgical ablation segment is expected to be the largest contributor to the tumor ablation market in 2016

Surgical tumor ablation is a minimally invasive surgical procedure in which ablation probes/catheters are used to deliver energy directly to the cancer site for treatment. This does not involve surgical removal of affected tissues or tumors. Surgical ablation is performed on patients ineligible for the surgical removal of tumor/cancer tissue.

The stable market growth witnessed by the surgical tumor ablation segment is mainly due to the large number of minimally invasive surgical procedures performed in mature markets (such as the U.S., the U.K., Italy, Germany, and Japan) to treat various cancers, growing market awareness about the benefits of surgical ablation in emerging markets (coupled with rapid modernization of regional healthcare infrastructure), and large proportion of cancer patients ineligible for surgical cancer treatment (paired with growing patient base for key cancers such as liver, kidney, lung, and prostate).

North America is expected to account for the largest share of the market during the forecast period

North America is one of the major revenue-generating regions in the global tumor ablation market. The large share of this regional segment can mainly be attributed to early introduction of tumor ablation technologies in the region, continuous technological advancements occurring in the field of tumor ablation catheters, and growing private-public investments to develop innovative tumor ablation technologies (coupled with the growing public awareness related to the benefits of tumor ablation).

Key Market Players

The tumor ablation market is a diverse and highly competitive market with a large number of players. Some of the prominent players in the tumor ablation are Medtronic, Plc (U.S.), AngioDynamics, Inc. (U.S.), HealthTronics, Inc. (U.S.), Galil Medical, Inc. (U.S.) and Boston Scientific Corporation (U.S.).

Medtronic is one of the key global manufacturers of tumor ablation products; with strong brand positioning across developed markets (such as the U.S., Japan, and Germany). The company focuses on both organic (product development and new product launches) and inorganic (strategic acquisitions and collaborations) growth strategies to further strengthen its footprint in the global tumor ablation market. The acquisition of Covidien Plc (Ireland) for USD 42.9 billion (January 2015) was a key development for Medtronic. This acquisition helped Medtronic to enter the tumor ablation businesses and expand its geographic presence. Other significant developments include: securing FDA pre-marketing approval for the Emprint ablation System (July 2014) and launch of the HALO90 ULTRA Ablation Catheter (July 2014)

AngioDynamics, Inc. is among the prominent market players in global tumor ablation industry. The company offers several innovative tumor ablation products (such as NanoKnife system, StarBurst RFA system, and UniBlate RFA electrodes); which helped the company to position itself among leading players in this segment. The company pursued strategic acquisitions and expansion of its existing product portfolio as its key growth strategy. During 2013-2016, the company undertook several key acquisitions that helped AngioDynamics to strengthen its market positioning and geographic presence; such as acquisition of Microsulis Medical Ltd. (U.S.) and Navilyst Medical Inc. (U.S.). The company is particularly focused on technological development and commercialization of its NanoKnife ablation system; pertaining to product�s excellent clinical results obtained during cancer treatment studies.

Recent developments:

In October 2015, AngioDynamics, Inc. launched its NanoKnife Ablation system in South Korea after receiving regulatory approval by Ministry of Food and Drug Safety (South Korea). This helped AngioDynamics expand its product portfolio for tumor ablation market

In July 2016, Boston Scientific Corporation acquired the Cosman Medical Inc. (U.S.) at an undisclosed value. Cosman Medical is a leading manufacturer of radiofrequency ablation devices. This acquisition helped Boston Scientific to strengthen its technological capabilities and to expand its product sales and distribution network in the global tumor ablation market

In May 2016, Galil Medical Inc. was acquired by the BTG plc group (a part of BTG International Ltd, U.K.); for a value of USD 110.0 million. BTG International is prominent manufacturer of cryoablation products and possesses strong product distribution network across Europe. The acquisition helped Galil Medical to strengthen its technological capabilities and to expand its distribution network in global tumor ablation market

In april 2016, Medtronic plc launched Barrx 360 Express radiofrequency ablation (RFA) balloon catheter; for the treatment of Barrett's esophagus. It helped the company to provide technologically advanced product to its customers in tumor ablation market

Key questions addressed in the report:

What are the growth opportunities related to tumor ablation across major regions in the future?

Emerging countries have immense opportunities for the growth and adoption of tumor ablation products. Will this scenario continue in the next five years?

Where will all the advancements in products offered by various companies take the industry in the mid- to long-term?

What are the new trends and advancements in the tumor ablation market?

To speak to our analyst for a discussion on the above findings, click Speak to Analyst